{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385886","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-09-09T11:10:06+00:00","discovered_at":"2026-09-09T11:15:00.862825+00:00","generated_at":"2026-09-09T11:15:18.929003+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tyra reports positive SURF302 data: 79% ORR, 57% CR at 60mg in FGFR3-altered NMIBC","bullets":["SURF302: 60mg QD ORR 79% (11/14), CR 57% (8/14) at 3 months; 50mg ORR 67%, CR 33%.","Safety: no Grade 4/5 TEAEs; Grade 3 treatment-related AEs in 4.5% (2/44), none at 60mg; no dose reductions at 60mg.","Exposure-response: ORR 86% above AUC 2500 vs 58% below; supports 60mg adjuvant, 70mg cohort planned for ablative.","Plans: complete 60mg enrollment, initiate 70mg cohort, engage health authorities; registrational adjuvant study expected 2027.","Also: SURF303 first patient CR at 3 months; BEACH301 cleared fifth dose level in achondroplasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385886","json":"https://secwatch.observer/filing/0001193125-26-385886.json","markdown":"https://secwatch.observer/filing/0001193125-26-385886.md","text":"https://secwatch.observer/filing/0001193125-26-385886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/0001193125-26-385886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T11:15:18.929003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}